Contacts

MedinCell announces three new products entering regulatory development

February 2, 2021

In vivo studies demonstrated the feasibility of three new long-acting injectable treatments: mdc-GRT (organ transplant), mdc-KPT (pain / animal health) and mdc-TTG (Covid-19)
The MedinCell team has selected the lead formulation and started the regulatory preclinical development of those three programs.


« With the admission of three new products into preclinical development and the achievement of this milestone for our contraceptive program last April, our team has achieved its goals” stated Christophe Douat, CEO of MedinCell. “The most advanced product of our portfolio – whose pivotal Phase 3 ended with positive results – is only the tip of the iceberg. On top of this product which is about to enter the final stage of the approval process, Phase 3 should start this year for two other products”.

The three new programs into regulatory development are:
• mdc-GRT: organ transplant – molecule: Tacrolimus
This treatment is intended to prevent graft rejection in organ transplant patients. It uses Tacrolimus, an immunosuppressant already widely used, as the active ingredient. In addition, to improve compliance, a major issue in patients who have received a transplant associated with a necessary lifelong treatment, this product could reduce the risk of adverse effects. The regulatory activities that have just begun should make it possible to launch the first-in-human study in 2022.

• mdc-KPT: pain in animal health – molecule: confidential
MedinCell’s first animal health program, mdc-KPT is a 5- to 7-day treatment targeting acute pain for pets, based on an active ingredient already widely used. The regulatory activities, which have just started, should enable the beginning of the product’s clinical trials before the end of 2021.

• mdc-TTG: Covid-19 – molecule: Ivermectin
The objective of MedinCell’s mdc-TTG program is to protect humans from Covid-19 and its variants with a long-acting injection of Ivermectin. A first formulation candidate potentially active for more than a month has entered regulatory preclinical development. The context of the pandemic could lead to approval in 2022.

In addition, in April 2020, MedinCell announced the regulatory development of the mdc-WWM program, a contraceptive administered by subcutaneous injection, fully bioresorbable and active for six months. This program is developed with the support of The Bill & Melinda Gates Foundation through a grant of up to $19 million over four
years to fund preclinical activities and initial clinical studies, scheduled to begin in 2023.

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.